Vatalanib, also known as PTK787, is an orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.
相关文献及参考
Wood, J.M., et al.: Cancer Res., 60, 2178 (2000),
Morgan, B., et al.: J. Clin. Oncol., 21, 3955 (2003),
安全信息
GHS Symbol
Safety Statements
Precautionary statements
Signal word
Risk Statements
Storage condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).